Nice | Rivaroxaban for DVT treatment

21st August 2012 by Louise Hudman

This guideline advises that Rivaroxaban can now be considered for use in the treatment of proximal DVT. It is as effective as warfarin, but is more expensive. I suspect we will need to await local approval before use. It doesn’t require monitoring.

It is contraindicated with GFR < 30 and ‘very high blood pressure’ among other things. Use is normally for 3m, though may be needed for longer if there are ongoing risk factors for VTE. It hasn’t really been studied beyond 12m, so use beyond that is of uncertain effectiveness (though is allowed).

Interestingly, there is a higher risk of non-major bleeding with rivaroxaban than on warfarin, though a similar rate of major bleeding.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I don’t normally do this, but just to say that I thought your article at the front of the latest NASGP magazine about clinical errors was really excellent. Great, and very thoughtful writing. NASGP member."

‘Great, and very thoughtful writing’

‘Great, and very thoughtful writing’

See the full list of features within our NASGP membership plans

Membership